International Journal of Radiation Oncology * Biology * Physics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

HyperlynX: A Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and Radiotherapy in Patients with Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The current standard of care for patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is cisplatin 100 mg/m2 every 3 weeks (Q3W) with concomitant radiotherapy (RT). Cisplatin once a week (QW) (NCCN Guidelines Category 2B and ESMO Guidelines II, A) is an alternative regimen to cisplatin 100 mg/m2 Q3W that is increasingly being adopted given the unfavorable adverse event profile of cisplatin 100 mg/m2 Q3W and the improved hydration associated with the QW regimen; however, direct comparisons from randomized confirmatory clinical trials in the definitive setting are pending. (Source...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: N.F. Saba, A. Sukari, F. Forget, A. Popovtzer, J. Rubio Perez, J.H. Park, M.H. Yang, M. Sato, M. Kuipers, R. Ito, S. Salmio Tags: 115 Source Type: research

A Vaccine (PDS0101) Alone or in Combination with Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
PDS0101 is a novel, investigational HPV-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers utilizing a mixture of HPV16 E6 and E7 peptides pools delivered subcutaneously with cationic (positively charged) lipid nanoparticles. Initial studies of PDS0101 in combination with pembrolizumab in patients with metastatic HPV16-positive recurrent/metastatic HNSCC demonstrated clinical activity with notable polyfunctional HPV16-specific CD4 and CD8 T cell activation. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: D.M. Routman, K. Van Abel, K. Bartemes, N.R. Foster, N. Riebel, L. Wood, A.A. Nagelschneider, J.J. Garcia, A.V. Chintakuntlawar, K. Price Tags: 116 Source Type: research

Outcomes in Patients with Oral Cavity Squamous Cell Carcinomas with Respect to Initiation of Chemotherapy and Adjuvant IMRT Timing
Patients with advanced oral cavity squamous cell carcinoma (OCSCC) have high recurrence rates. The current treatment paradigm consists of definitive surgery followed by risk-adapted adjuvant radiation therapy (RT) with or without concurrent chemotherapy. We hypothesized that initiating chemotherapy on the same day as RT and shorter interval between surgery and starting RT would improve oncological outcomes. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: K.R. Cargill, J.A.A. Vargo, U. Iheagwara, S. Kim, M.W. Kubik, S. Sridharan, U. Duvvuri, D.P. Zandberg, Z. Rahman, R. Seethala, J.P. Zevallos, R. Ferris, H.D. Skinner, Y.M. Mowery, C.T. Wilke Tags: 117 Source Type: research

Predictors of Occult Nodal Involvement in Clinically Node Negative Primary Parotid Carcinoma: An Updated NCDB Analysis
Primary Parotid Carcinomas (PPC) comprise a wide array of histologies, each with varying propensity for local invasion and cervical nodal involvement. Upfront surgical excision of the primary tumor constitutes the standard of care for PPC, but there exists little consensus regarding management of the clinically negative neck (cN0). We conducted a clinicopathologic correlative analysis of the National Cancer Database (NCDB) to identify predictors of occult nodal involvement in PPC to guide elective neck management. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J. Lorenz, Y. Liu, S. Goyal, J.S. Remick, S.F. Rudra, S. Hanasoge, D.S. Yu, N.C. Schmitt, C. Steuer, K.R. Magliocca, W.A. Stokes Tags: 118 Source Type: research

Combinatorial Immunotherapy and Associated Tumor Metabolic Stress in Pre-clinical HNSCC Mmodels
The combination of conventionally fractionated radiation (conRT) and anti-PD1/PD-L1 has underperformed, speaking to a lack of understanding in the interaction between conRT and the immune response. To begin to address this issue, we have undertaken a comprehensive evaluation of conRT and PD-1/PD-L1 in pre-clinical models. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: A. Gopalkrishnan, L. Yang, B. Leibowitz, A. Hefner, M. Elfayoumi, S. Basu, J. Wang, C. Pickering, H.D. Skinner Tags: 119 Source Type: research

Tubarial Gland Sparing with Intensity-Modulated Radiation Therapy for Oropharyngeal Cancers: A Pilot Study of Dosimetric Feasibility
In this study, we hypothesized that intensity-modulated radiation therapy (IMRT), which is widely utilized in the treatment of oropharyngeal carcinoma, would reduce the mean dose to the tubarial glands without a significant difference in target coverage. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: N.S. Kalman, S. Yarlagadda, N. McAllister, A.E. Rzepczynski, T. Kutuk Tags: 120 Source Type: research

EVOLVE: Evaluating the Safety of and Quality of Life in De-escalated Head and Neck Irradiation in HPV  + Oropharynx Cancer in Non/Minimal Smokers in the Community Setting
Previous studies at large academic centers have shown that de-escalation of adjuvant radiotherapy for selected patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma in non-smokers/minimal smokers has similar rates of disease control with reduced toxicity and stable quality of life. The purpose of this study was to confirm the reproducibility of these findings in a community cancer center setting. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: I. Ailts, M.J. Blanchard, A. Terrell, R. Vegunta, S. Powell, R.K. Nowak, A. Schmidt, L. Geeraerts, S.R.W. Nurkic, A.W. Jensen, C. Ellison, D. Sturdevant, W. Spanos Tags: 121 Source Type: research

Predictors of Treatment Failure in Young, Non-Smoking, Non-Drinking Patients with Squamous Cell Carcinoma of the Oral Tongue
A history of significant alcohol and tobacco use are known risk factors for the development of squamous cell carcinoma of the oral tongue (SCCOT). Despite a documented rise in disease incidence in young patients with no known risk factors, little is understood about the pathogenesis and clinical outcomes in this cohort. High rates of treatment failure in these patients, when compared to older patients with SCCOT and no risk factors, warrants further study. We aim to identify specific demographic, clinical, or pathological predictors of treatment failure in young, SCCOT patients with no prior drinking or smoking history. (S...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: N. Rodriguez, D.R. Dickstein, K. Sindhu, J.T. Liu, J. Barlow, S. Reed, W.H. Westra, D. Kirke, M.V. Gerwen, M. Posner, D.K. Misiukiewicz, S. Roof, E. Genden, R.L. Bakst Tags: 122 Source Type: research

Prognostic Factors for Locoregional Control in Early-Stage Oral Tongue Squamous Cell Carcinoma Treated with Partial Glossectomy and Elective Neck Dissection
Patients with early-stage oral tongue squamous cell carcinoma (OTSCC) are generally considered low-risk for recurrence and typically do not receive adjuvant radiotherapy. We aimed to identify pathologic factors associated with locoregional recurrence in this population. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: M. Modzelewski, J. Abrahams, A. Beighley, M. McNicoll, A. Lin, A. Larson, J. Chen, M. Zhi, S. Iganej, O. Bhattasali Tags: 123 Source Type: research

A Phase II Trial of Xevinapant in Combination with Post-Operative Cisplatin and Radiotherapy for High Risk Head and Neck Cancer
Patients with head and neck squamous cell carcinoma (HNSCC) who have high risk clinicopathologic factors after surgery are at high risk for locoregional recurrence despite multimodal therapy. This risk is particularly high for patients who are found to have early recurrence during preparation for post-operative radiotherapy. Xevinapant is an oral inhibitor of apoptosis (IAP) antagonist that has demonstrated early evidence of efficacy in combination with 7 weeks of radiation and cisplatin in a phase II trial, with a tolerable safety profile. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: Y. Yu, I. Ganly, E. Sherman, N.Y. Lee Tags: 124 Source Type: research

Patterns of Recurrence and Predictors of Outcome in Cervical Esophageal Carcinoma Patients Treated with Definitive Chemoradiation
Cervical esophageal carcinoma (CEC) is a rare form of esophageal cancer that is typically locally advanced at diagnosis and often carries a poor prognosis. The aim of this study was to evaluate patterns of recurrence and therapy-related toxicities in patients treated with chemoradiation therapy (CRT). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: A. Gan, J.M. Bryant, R.J. Cruz-Chamorro, M. Echevarria, K. Kirtane, J.A. Kish, C.S. Chung, J.J. Caudell, G.Q. Yang Tags: 125 Source Type: research

Adjuvant Treatment Deintensification after Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
The safety and oncologic efficacy of a primary surgical approach, or transoral robotic surgery (TORS) with neck dissection, is well-established for early stage OPSCC. Given high rates of survival, particularly for human papillomavirus (HPV)-associated OPSCC, there is increasing interest in treatment deintensification strategies. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J.L. Farlow, A.J. Jones, D.X. Xie, D.W. Chen, D.A. Campbell, A. Mantravadi, M.G. Moore, G. Durm, M.P. Langer, J. Yesensky, M. Sim Tags: 126 Source Type: research

Implications of Rapid Molecular Responses to Induction Chemotherapy (IC) in Human Papilloma Virus (HPV) Head and Neck Squamous Cell Carcinoma (HNSCC).
Patients with locally advanced (LA) HPV HNSCC are treated with various types of IC and/or standard (sd) or reduced dose (rd) of chemoradiation (CRT). Chemotherapy only (TPF) or with immunotherapy (TP-PD1) are the main IC types used prior to CRT or surgery. Tumor tissue modified viral HPV DNA (TTMV) is a sensitive and specific biomarker for HPV+ HNSCC. Therefore, TTMV may be useful to match patients with the appropriate intensity of treatment while minimizing toxicity. However, how TTMV levels may be used to guide the treatment of HNSCC is not yet established. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: L. Worona, M. Dougherty, E. Ramos, R.L. Bakst, K. Sindhu, S. Roof, W.H. Westra, E. Genden, M. Posner, D.K. Misiukiewicz Tags: 127 Source Type: research

ENID: Phase II Trial of Definitive Chemoradiation with Elective Nodal Irradiation Dose De-Escalation for P16 Positive Squamous Cell Carcinoma of the Oropharynx
HPV-related oropharyngeal squamous cell carcinomas (OPSCCs) have a better overall prognosis and head and neck irradiation is associated with significant acute and late toxicities, therefore this has been an area of active evaluation of de-escalation strategies. Among them is a reduced dose to the elective lymph nodes. The purpose of this study is to report the initial evaluation of lower dose (40 Gy in 20 fractions) to the elective lymph nodes while delivering usual high dose (70 Gy in 35 fractions) to the FDG PET defined gross disease. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: G.B. Biedermann, L. Dooley, J. Overschmidt Tags: 128 Source Type: research

Arytenoid-Sparing Intensity-Modulated Radiotherapy for Early-Stage Glottic Cancer
In this study, we demonstrate initial dosimetric results of a novel approach called arytenoid-sparing IMRT (AS-IMRT), which is aimed at reducing speech and swallowing toxicity. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: A. Rybkin, J. Scott, M.R. Young, H.S.M. Park Tags: 129 Source Type: research